Cargando…
From On-Target to Off-Target Activity: Identification and Optimisation of Trypanosoma brucei GSK3 Inhibitors and Their Characterisation as Anti-Trypanosoma brucei Drug Discovery Lead Molecules
Human African trypanosomiasis (HAT) is a life-threatening disease with approximately 30 000–40 000 new cases each year. Trypanosoma brucei protein kinase GSK3 short (TbGSK3) is required for parasite growth and survival. Herein we report a screen of a focused kinase library against T. brucei GSK3. Fr...
Autores principales: | Woodland, Andrew, Grimaldi, Raffaella, Luksch, Torsten, Cleghorn, Laura A T, Ojo, Kayode K, Van Voorhis, Wesley C, Brenk, Ruth, Frearson, Julie A, Gilbert, Ian H, Wyatt, Paul G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
WILEY-VCH Verlag
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728731/ https://www.ncbi.nlm.nih.gov/pubmed/23776181 http://dx.doi.org/10.1002/cmdc.201300072 |
Ejemplares similares
-
The Design and Synthesis of
Potent and Selective Inhibitors
of Trypanosoma brucei Glycogen Synthase
Kinase 3 for the Treatment of Human African Trypanosomiasis
por: Urich, Robert, et al.
Publicado: (2014) -
Optimisation of the Anti-Trypanosoma brucei Activity of the Opioid Agonist U50488
por: Smith, Victoria C, et al.
Publicado: (2011) -
Investigation of Trypanothione Reductase as a Drug Target in Trypanosoma brucei
por: Spinks, Daniel, et al.
Publicado: (2009) -
An Essential Farnesylated Kinesin in Trypanosoma brucei
por: Engelson, Erin J., et al.
Publicado: (2011) -
Development of Small-Molecule Trypanosoma brucei N-Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode
por: Spinks, Daniel, et al.
Publicado: (2015)